JP7582970B2 - Ｗｅｅ１阻害剤化合物の結晶形及びその応用 - Google Patents

Ｗｅｅ１阻害剤化合物の結晶形及びその応用 Download PDF

Info

Publication number
JP7582970B2
JP7582970B2 JP2021564588A JP2021564588A JP7582970B2 JP 7582970 B2 JP7582970 B2 JP 7582970B2 JP 2021564588 A JP2021564588 A JP 2021564588A JP 2021564588 A JP2021564588 A JP 2021564588A JP 7582970 B2 JP7582970 B2 JP 7582970B2
Authority
JP
Japan
Prior art keywords
crystalline form
pattern
compound
formula
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530812A (ja
Inventor
文▲遠▼ ▲銭▼
▲純▼道 ▲楊▼
正▲偉▼ 李
▲ジエ▼ 李
健 黎
曙▲輝▼ ▲陳▼
Original Assignee
ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド filed Critical ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド
Publication of JP2022530812A publication Critical patent/JP2022530812A/ja
Application granted granted Critical
Publication of JP7582970B2 publication Critical patent/JP7582970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021564588A 2019-04-30 2020-04-30 Ｗｅｅ１阻害剤化合物の結晶形及びその応用 Active JP7582970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910364694 2019-04-30
CN201910364694.X 2019-04-30
PCT/CN2020/088451 WO2020221358A1 (zh) 2019-04-30 2020-04-30 Wee1抑制剂化合物的晶型及其应用

Publications (2)

Publication Number Publication Date
JP2022530812A JP2022530812A (ja) 2022-07-01
JP7582970B2 true JP7582970B2 (ja) 2024-11-13

Family

ID=73029676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564588A Active JP7582970B2 (ja) 2019-04-30 2020-04-30 Ｗｅｅ１阻害剤化合物の結晶形及びその応用

Country Status (21)

Country Link
US (1) US12291536B2 (https=)
EP (1) EP3964510B1 (https=)
JP (1) JP7582970B2 (https=)
CN (1) CN113784968B (https=)
AU (1) AU2020266956B2 (https=)
BR (1) BR112021021230A8 (https=)
CA (1) CA3138240C (https=)
DK (1) DK3964510T3 (https=)
ES (1) ES2984617T3 (https=)
FI (1) FI3964510T3 (https=)
HR (1) HRP20241008T1 (https=)
HU (1) HUE068061T2 (https=)
IL (1) IL287472A (https=)
LT (1) LT3964510T (https=)
PL (1) PL3964510T3 (https=)
PT (1) PT3964510T (https=)
RS (1) RS65747B1 (https=)
SG (1) SG11202111315XA (https=)
SI (1) SI3964510T1 (https=)
SM (1) SMT202400303T1 (https=)
WO (1) WO2020221358A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018171633A1 (zh) 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
CA2667345C (en) * 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
EP2477628B1 (en) 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9181239B2 (en) 2011-10-20 2015-11-10 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
JP6692423B2 (ja) 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
SG11202003974XA (en) * 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018171633A1 (zh) 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
ES2984617T3 (es) 2024-10-30
SG11202111315XA (en) 2021-11-29
CA3138240C (en) 2025-04-01
BR112021021230A2 (https=) 2021-12-21
RS65747B1 (sr) 2024-08-30
US12291536B2 (en) 2025-05-06
SI3964510T1 (sl) 2024-10-30
BR112021021230A8 (pt) 2023-04-25
IL287472A (en) 2021-12-01
PT3964510T (pt) 2024-07-29
AU2020266956B2 (en) 2025-05-08
CN113784968A (zh) 2021-12-10
PL3964510T3 (pl) 2024-08-19
CN113784968B (zh) 2024-03-15
HRP20241008T1 (hr) 2024-11-08
JP2022530812A (ja) 2022-07-01
HUE068061T2 (hu) 2024-12-28
SMT202400303T1 (it) 2024-09-16
EP3964510A1 (en) 2022-03-09
FI3964510T3 (fi) 2024-07-24
EP3964510B1 (en) 2024-07-03
EP3964510A4 (en) 2023-04-26
US20220220120A1 (en) 2022-07-14
AU2020266956A1 (en) 2021-10-28
DK3964510T3 (da) 2024-07-29
CA3138240A1 (en) 2020-11-05
WO2020221358A1 (zh) 2020-11-05
LT3964510T (lt) 2024-08-12

Similar Documents

Publication Publication Date Title
JP7582970B2 (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
JP7573019B2 (ja) Ａｔｒ阻害剤の結晶形及びその使用
EP2985277B1 (en) Method for preparing an atropisomer of a pyrrole derivative
EP2949647A1 (en) Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same
KR20130122612A (ko) 오에스아이 906의 다형체
WO2022166994A1 (zh) 一种萘基脲类化合物、其制备方法及应用
US20240391896A1 (en) Small molecule compound targeting bcl9/beta-catenin interaction
JP7282780B2 (ja) ４－（ナフタレン－１－イル）－４ｈ－１，２，４－トリアゾール系化合物の結晶形、塩形態及びその製造方法
CN117355528B (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
RU2842334C2 (ru) Кристаллическая форма ингибирующего wee1 соединения и ее применение
HK40060045A (en) Crystal form of wee1 inhibitor compound and use thereof
HK40060045B (zh) Wee1抑制剂化合物的晶型及其应用
WO2020224585A1 (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
CN114644615B (zh) 一种吲唑类衍生物的结晶形式及其制备方法
RU2832707C2 (ru) Кристаллическая форма ингибитора atr и ее применение
CN110590663A (zh) 一种1，8-萘酰亚胺衍生物及其应用
EP4467536A1 (en) Crystalline form of sulfur-containing isoindoline derivative
HK40074313B (zh) 一种atr抑制剂的晶型及其应用
JP2025510077A (ja) １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物の結晶形及びその製造方法
HK40074313A (en) Crystalline form of atr inhibitor and use thereof
HK1241358A1 (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
HK1221214B (en) Method for preparing an atropisomer of a pyrrole derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241031

R150 Certificate of patent or registration of utility model

Ref document number: 7582970

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150